【Video】A precious anniversary
- Shimadzu's Response to Dementia -
Our Response to Dementia
Researchers’ Passion and Study of Blood-based Biomarkers - Useful for Early Detection of Alzheimer’s Disease
Akinori Nakamura
Doctor of Medicine/Neurologist
Professor, Department of Biomarker Research, The National Center for Geriatrics and Gerontology
From Ultra-early Diagnostics to Prognosis Management of Dementia
- Ultra-early Diagnostics
- Diagnostics
- Treatment
- Prognosis
Amyloid-MS
Predicting Amyloid-beta Deposition Levels in the Brain from a Blood Test
BresTome TOF-PET Scanner
Visualizing Amyloid-beta Deposition in the Brain using PET Imaging
fNIRS
Evaluating Cognitive Function by Optical Brain Function Imaging
Related Information
Please contact us for any materials you are interested in.
Technical Information
Conference
Luncheon Seminar 16
Amyloid biomarkers of dementia
- Date
- September 10, 2022(Sat.)
12:30～13:30
- Place
Kyoto International Conference Center Room5（Room B-1）
- Chairman
-
Dr. Hidehiko Okazawa
Professor, University of Fukui, Biomedical Imaging Research Center
- Speaker 1
-
Blood-based biomarkers for dementia: Current status and future directions
Dr. Akinori Nakamura
Professor, Department of Biomarker Research, National Center for Geriatrics and Gerontology
- Speaker 2
-
High resolution dedicated head PET scanner for molecular imaging of dementia
Dr. Kazunari Ishii
Chief Professor, Kindai University Faculty of Medicine, Department of Radiology
*This seminar will be conducted in English.
Work in Progress
- Date
- September 9, 2022 (Fri.)
15:15～17:15
(Five companies, including Shimadzu, will present.)
- Place
Kyoto International Conference Center 2F（Room 4)
- Title
-
BresTome TOF-PET system and Advanced Healthcare of Shimadzu
Yoshiyuki Yamakawa
Research & Development Department, Medical Systems Division, Shimadzu Corporation
For more details: https://www.shimadzu.eu/aaic-2020
- Poster
-
MALDI-TOF IP-MS quantification of plasma amyloid peptides in Alzheimer’s disease
Sylvain Lehmann, CHU Montpellier, France
- Poster
-
Identification of ADAMTS4 as an APP-cleaving enzyme at 669 site in APP669-711 production pathway
Taisuke Tomita, The University of Tokyo, Japan
- Poster
-
Plasma Aβ biomarker associated with cognitive decline in preclinical Alzheimer’s disease
Yen Ying Lim, The Florey Institute of Neuroscience and Mental Health, Australia
- Poster
-
Studies on the Pragmatic Performance and Validity of a Plasma Amyloid β Measurement System by Immunoprecipitation-Mass Spectrometry
Naoki Kaneko, Shimadzu Corporation, Japan
For more details: https://www.shimadzu.eu/aaic-2021
- Poster
-
Semi-quantitative assay for Neurogranin peptides using IP-MALDI-MS
Naoki Kaneko, Shimadzu Corporation, Kyoto, Japan
- Poster
-
Analytical Validation of Plasma Amyloid β Measuring System by Immunoprecipitation-Mass Spectrometry
Ritsuko Yoda, Shimadzu Corporation, Kyoto, Japan
- Poster
-
The APP669-711/Aβ1-40 ratio as a plasma biomarker specific for the brain Aβ deposition in APP/PS1 mouse
Naoki Kaneko, Shimadzu Corporation, Kyoto, Japan
For more details: https://www.shimadzu.eu/msacl-eu-21
- Corporate Workshop
-
Blood test for neurodegenerative diseases: Are we ready? - Implementation of high-performance plasma amyloid-beta quantification for Alzheimer's diagnostic on the Clinical Proteomics Platform of Montpellier Hospital (France)
Pr. Christophe Hirtz, PPC, IRMB, Hospital Saint Eloi, Montpellier, France (general presentation)
Jana Kindermans, PPC, IRMB, Hospital Saint Eloi, Montpellier, France (analytical validation, clinical validation)
Cohort research
Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias
PhD, MD, Daniel Alcolea, Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Barcelona (Spain)
Journal of Neurology, Neurosurgery & Psychiatry